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S_ry Although expression of the bcl-2 proten has been investgated in a number of non-haematological
malignanies, little is known of its distribution in premalignant ksions. Expression of bcl-2 was investigated
immunohistochemically in archival biopsies of normal (n = 8) and dysplastic bronchial epitheium (n = 56) and
in 31 bronchial resection margins and their corresponding carcinomas. All dysplasias had lost the pro t
basal staining pattern seen in histologically normal epithelium. Two were negative and six had oconal basal
positive ceIls. In 37 ca up to 66% of the epitheial cells throughout the full epithelial thickness were bl-2
positive with weak to moderate staining intensity. In 11 cams, all severe dysplasias, strong expresson was
observed in >90% of the epithelial cells. Four patterns ofbcl-2 expression in dysplasias wereidentified and an
increasinly aberrant pattern of bd-2 expression coirelated with an inc g grade of dysplaia (Spearman's
rank correlation, P < 0.0001). Sixty-five per cent of the carcinomas contained bcl-2-positive cells. Patients with
non-sma-cell hmg cainomas (n = 27) in which >50% of the tumour cells were bcl-2 positie showed a
survival advantage compared with those with 0-25% bcl-2-positive cells (P = 0.02). No correlation was found
between p53 exprsson (Walker et al., 1994) and bcl-2 expression in dysplasias or carcnomas.
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Lung cancer is the commonest cancer in the UK, accounting
for one in six of all new cancer cases (Cancer Research
Campaign, 1992). Most patients present with already
advanced diseas, and the prognosis remains poor despite
improvements in clinical treatment (Roth, 1992; Souhani,
1992; Gazdar, 1994). Conventional screening studies for early
detection have had little effect on overall survival (Frost,
1986; Tockman et al., 1992), possibly because lesions that are
clinically informative may have already progressed to
disseminated disease (Gazdar, 1994).
Lung carcinomas arise after a series of morphological and
genetic changes within the bronchial epithelium, and it may
take years to progress from normal epithelium to invasive
cancer. The morphological changes are thought to progress
from hyperplasia, to metaplasia/dysplasia, to carcinoma in
situ and finally to invasive and metastatic cancer (Gazdar,
1994; Lee, 1992). Improvements in the treatment of this
disease which may prolong survival rely on early recognition
of the molcular changes at a time of absent or minimal
histopathological change before the acquisition of
invasiveness (Gazdar, 1994).
Moleular and cytogenetic changes have been described in
preinvasive bronchial ksions (Sundaresan et al., 1992) as well
as in normal epithelium adjacent to lung cancers (Lee et al.,
1987, 1992; Sozzi et al., 1991). Abormal expression of the
p53 protein has been reported in dysplastic bronchial
epithelium and in normal bronchial epithelium of cancer
patients (Bennett et al., 1993; Nuorva et al., 1993; Hirano et
al., 1994; Walker et al., 1994), suggesting that aberration in
p53 function may be a very early process in the development
oflung cancers. Such studies prompt further investigations to
establish the nature of the changes in dysplastic epithelial
cells which may be involved in the development ofmalignant
potential.
The bcl-2 gene codes for a 26 kDa protein with lipophilic
character and no substantial homology with any other proto-
oncogene products (Cleary et al., 1986; Tsujimoto and Croce,
1986; Hockenbery et al., 1990) and may contribute to malig-
nancy by preventing programmed cell death or apoptosis
(Hockenbery et al., 1990; Jacobson et al., 1993; Kerr et al.,
1993). This proto-oncogene was first described as a result of
the chromosomal translocation t(14; 18) seen in a laige
number of follicular B-cell lnes and the majority of malig-
nant human follicular B-ell lymphomas (Tsujimoto et al.,
1985; Korsmeyer, 1992). In this translocation the bcl-2 gene
on chromosome 18 becomesjuxtaposed with the IgH gene on
chromosome 14, resulting in overexpression of the bcl-2 pro-
tein, and conferring affected lymphocytes with reistance to
apoptosis (Ckary et al., 1986; Hockenbery et al., 1990). High
levels of bcl-2 expression prevent cell death from a wide
variety of cell stresses and cytotoxic cheicals, including
growth factor depletion, heat shock, ionising radiation,
excess calcium influx and a range of chemotherapeutic drugs
(Tsujimoto, 1989; Sentmen et al., 1991; Miyashita and Reid,
1992; Lotem and Sachs, 1993).
In oncogenesis, deregulation of bcl-2 expression may cont-
ribute to the accumulation of oncogenic mutations by supp-
ressing the apoptotic deletion of cells that normally follows
the induction of DNA damag (Kerr et al., 1993).
Pathological expression of bcl-2 has so far been investigated
mainly in haematologicl malignancies (Pezzella et al., 1990;
1991; Korsmeyer, 1992; Piris et al., 1994), but only in a few
epithelial or neural tumours (Castle et al., 1993; Leek et al.,
1994; Pilotti et al., 1994; Ramini and Lu, 1994; Segal et al.,
1994; Silvestrini et al., 1994). The bcl-2 protein is expressed in
some small-cell lung cancer (SCLC) cell lines (Ikegaki et al.,
1994) and in 28% of non-small-cell lung cancers (NSCLC)
(Pezzella et al., 1993). In NSCLC, bc)-2 positivity is
associated with better prognosis (Pella et al., 1993).
Although it is present in a number of lung carcinomas, bcl-2
is absent in differentiated cells of normal bronchial
epithelium (Pezzella et al., 1993). Pezzella et al. (1993) sug-
gest that the presence of bcl-2 in differentiated cells may be
an indicator of malignancy, but before drawing such conc-
lusions some knowledge of the expression of this molecule in
premalignant lesions would be useful.
In this study, we have investigated immunohistochemically
the expression of the bcl-2 protein in normal and dysplastic
bronchial epithelium and in lung carcinomas. Comparison
has been made with the expression ofthe p53 protein in these
tissues, detrmined previously (Walker et al., 1994).
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Lung tssues
Fifty-six formalin-fixed, paraffin-embedded bronchial biopsies
which had been reported to contain dysplastic epithelium
were retrieved from the archives at the Histopathology
Department, Broadgreen HospitaL Liverpool, UK. In the
majority of cases there was a concomitant diagnosis of lung
cancer. Dysplasia was graded as mild, moderate or severe as
described in Pendleton et al. (1993). Eight formalin-fixed,
paraffin-embedded bronchial biopsies and four resction mar-
gins, taken from patients who did not have lung cancer at the
time of removal and which contained epithelium reported as
histologically normal, were also obtained from the files.
Thirty-one formalin-fixed, paraffin-embedded specimens of
lung carcinoma and their corresponding bronchial resection
margins were colleted prospectively by Dr N Pendleton
from lobectomies or pneumonectomies performed at the Car-
diothoracic Centre, Liverpool, UK. Patients received no
other form of therapy either before or after surgery and were
staged using UICC guidelines. Full clinical data were
available for these cases.
Imunnohistochemistry
Bcl-2 immunoreactivity was determined using methods
similar to those described in Walker (1994), except that
microwave antigen retrieval was essential. Sections were mic-
rowaved in 10 mM citrate buffer pH 6.0 for 20 min using a
650 W microwave oven at full power before staining. A
monoclonal antibody to bcl-2 (clone 124, Dako) was used at
1:40. Negative controls using normal rabbit serum at 1:400
or Tris-buffered saline (TBS) in place of the primary
antibody and lymphoid tissue as positive control were
included in each staining run. Lymphocytes in each section
acted as additional internal positive controls.
Sections were reviewed for bcl-2 positivity and the intensity
of stained cells scored as negative, weak, moderate or strong.
Weak staining was defined as that which was only apparent
at high magnifiction ( x 400), while moderate and strong
staining was visible at all magniiations. In normal and
dysplastic epithelium, the proportions of bcl-2-positive
epithelial cells and their distribution according to the thick-
ness of the epithelium containing these cells was recorded.
Dysplasias were classified into four categories (A-D) (Table
1) according to the number and distribution of positive cells
and their staining intensity. Inter-observer variability (x) for
this classification was 0.87 (95% confidence interval
0.77-0.97). In tumours, the distribution of stained tumour
cells across the sections was noted and the percentage of
positive cells assessed independently by two pathologists.
Immunoreactivity to p53 in cases that had not previously
been investigated was determined as described in Walker et
al. (1994) using the CMI antibody (Novaastra).
Statistical analysis
The signifa of associations were determined using the
Fisher-Irwin exact probability test or the chi-squared test.
Spearman's rank correlation was used to compare the
severity of dysplasia with bcl-2 staining patterns. Survival
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analysis was by the log-rank test. Two-tailed probabilities are
quoted for all statistical tests.
Relts
Normal epithelium
AU bronchial resection margins from lung cancer patients
(30/30), bronchial biopsies (8/8) and resected bronchial tis-
sues from non-cancer patients (4/4) showed a similar pattern
of immunohistochemical staining in histologically normal
epithelium when stained with a monoclonal antibody (clone-
124) to the bcl-2 protein AU cases examined showed long
stretches of normal epithelium positive for bcl-2, although
the intensity of stain varied between cases and within sec-
tions; in a few cases areas of epithelium negative for bcl-2
were present In bcl-2-positive regions of normal epithelium
basal cells were stained usually with a moderate to strong
intensity, while the more differentiated cells were negative,
resulting in a prominent basal staining pattern (Figure 1).
The intracellular distribution of this stain was cytoplasmic,
with many cells showing perinuclear membranous sining.
In some cases occasional brush border cells stained intensely
with similar intracellular distribution; sometimes these cells
were clearly ciliated.
Bronchial glands stained cytoplamically with variable
intensity, some being strongly stained. Perinuclear memb-
ranous stain was occasionally noted in glandular epithelial
cells. In all tissues scored, lymphocytes were strongly stained.
Dysplastic epithelium
Fifty-six bronchial biopsies with dysplastic epithelium were
investigated for expression ofthe bcl-2 protein. None showed
the pattern of staining typical of histologically normal
epitheliuim AU had lost the prominent basal layer of stained
cells seen in normal epithelium. In two cases dysplastic
epithelium was completely negative for bcl-2, although lym-
phocytes in the sections were positive. In 28 cases the inten-
sity of the stain in bcl-2-positive cells was weak. In the
lemaining 26 cases the intensity was similar to or increased
compared with bcl-2-positive normal epithelium. In all
positive dysplasias the proportion and distribution ofpositive
cells was asd. In six cases only a few positive very
weakly stained cells were evident in basal locations. In 37
cases bcl-2-positive cells of weak or moderate intensity were
found in suprabasal locations and in many cases extended
throughout the fuIl thickness ofthe epithelium. In these cases
positive cells were present in varying proportions, from focal
positivity to up to approximately two-thirds of the epithelial
cells. In 11 cases strong expression was observed in the
majority of the epithelial cells and throughout the full thick-
ness. In dyspWlaias all bcl-2-positive cells showed cytoplasmic
stain; some showed perinuclear membranous stain.
Occasional positive nuclei were observed both in cells in
mitosis and in cells not under going mitosis.
Based on the number and distribution of positive cells in
the epithelium and their staining intety, four patterns of
bcl-2 expression were identified (Table I and Figure 2).
Table I Expression ofthe bdl-2 protein in bronchial dysplasia
Bcl-2staiingpattern
A B C D
Intensity of Negative or Weak Moderate Strong
positive cells Weak
Distribution of Basal Up to full Up to full Full thkness
positive cells thickness thickness
Proportion of <5% Up to 66% Up to 66% >90%
stained cefls
Number of 8 22 15 11




Dysplasias of all histological grades showed bcl-2 staining
patterns A, B and C, while pattern D was only found in
severe dysplasia (Table II). Severe dysplasias with the most
pleomorphic cells showed the strongest stain. Comparing
mild and moderate dysplasias with severe dysplasias, pattern
A was more often found in the mild/moderate group
(P = 0.042), while pattern D was only found in the severe
Fuge 1 Expsion of the bcl-2 protein in histollly normal
bronchial epithelium. Scale bar= =O n.
a
b
Flge 2 Expression of the bc-2 protein in dyplasfic brnhial
epithelium. (a) Severe dysplasia showing staining pattern C (scale
bar = m). (b) Severe dysplasia showing staining pattern D
(scale bar = 20pam).
group (P = 0.004) (Table II). An increasingly aberrant pat-
tern (from A to D) correlated with an increasing grade of
dysplasia (Spearman's rank correlation coefficient of 0.49,
P < 0.0001). Thus, staining tended to be more prominent,
with a greater proportion of bcl-2-positive cells in the upper
layers of the epithelium with increasing severity of dysplasia.
In the system of categorisation given in Table I, groups B
and C differed only in the ining intensity of bcl-2-positive
cells. Even if groups B and C were combined in the Spear-
man rankl correlation analysis a trend towards the more
aberrant patterns of bcl-2 expression was still obtained as
severity of dysplasia increased (correlation coefficient of 0.46,
P = 0.0002).
Bcl-2 andp53 expression in dysplastic epitheliwn
For many of the samples of dysplastic epithelium examined
in this study, expression of p53 had already been investigated
(Walker et at., 1994). Where sufficient tissue was available,
new cases were also eamined for p53 expression using the
CMI antibody. There was no correlation betweii p53 exp-
ression and bcl-2 expression.
Bronchial carcinomas
As described above, the expression of the bcl-2 protein was
examined in the histologically normal epithelium in bronchial
margins from lung carcinoma resections. In the correspon-
ding carcinomas, 20/31 tumours and 16/27 NSCLCs con-
tained bcl-2-positive cells (Table Ill). Eklven out of 31
tumours were completey negative for bcl-2, even though
lymphoid tiss and, in many sections, adjacent normal
epithelium stained strongly. A further 14 tumours had bcl-2-
negative areas within the tumour. In some bcl-2-positive
tumours, staining was focal and patchy, although in positive
areas stain was evident in all tumour cells. In others bcl-2
was expressed more intensely at the periphery of tumour
islands. Six tumours showed intense stain throughout the
entire tumour. In the remaining positive tumours intensity
varied between the tumours and within the tumour sections
from weak to strong. In tumours stain was cytoplasmic and
in some cases perinuckar membranous. In some tumours
occasional clls, either in mitosis or with pleomorphic nucki,
showed intense nuclar staining for bcl-2.
Although the number of tumours investigated was small,
full clinical information was available for these cases. Bcl-2
expresson was found in all histological types (Table EII). No
correlation was found between the degree of differentiation,
the UICC stage or TMN score and bcl-2 expression.
A scatter diagam for the percentage bcl-2-positive tumour
cells in the 27 NSCLCs eamined in this study is shown in
Figure 3. In survival analysis for the NSCLC tumours in this
series, the tumour that had 1% tumour cells positive for bd-2
was included in either the negative group or the positive
group with no significnt difference to the results obtained.
No sigificnt survival advantage was shown for patients
with tumours which were negative for bcl-2 compared with
those with bcl-2-postie tumours (ogrank test 0-1% vs
20-100%, chi-squared 3.43, P = 0.06). In contrast, patients
in the group whose tumours had 50-100% bcl-2-positive
tumour cells had a significntly longr survival than those
with 0-25% bcl-2-positive tumour cells (Figure 4) (log-rankl
test 0-25% vs 50-100%, chi-squared 5.75, P = 0.02).
TAb B &I-2 expression and severity ofdisplasia
Bcl-2stainngpattern
Grade ofdyspJasia A B C D
Mild 4 5 2 0
Moderate 2 6 2 0
Severe 2 11 11 11
Mild + moderate vs severe: A vs B + C + D, P = 0.042* (Fisher's
exacttest);A + BwsC + D, P = 0.0040(chi-squaredtest);A + B + C vs
D, P = 0.004* (FLsber's exact test). *Two-tailed probabilities.&d,2 in'. Pr.-c am ~ i..
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Tie m E ofbcl-2 in lung arcnos
Bcl-2poitivity
Any twnour >200% twnour > SO. twnour
Histology cellspositive cellspositie cellspositiWe
Squamous ell carcinoma 8 7 5
(n = 14)
Adenocarcinomas 6 6 5
(n= 11)
- carcinomas 1 1 1
(n= 1)
Smal-ei winomas 1 1 1
(n = 1)
SCLC/squamous cinomas 1 1 1
(n=I)
Adenosquamous carcnomas 1 1 1
(n= 1)
Carcinoids 2 1 0
(n = 2)
NSCLC 16 15 12
(n = 27)





















F.gwe 3 Scatter diagram for bcl-2 positivity in NSCLC.
50-100% bc-2-posifive tumour cells
1, ~~~~(n = 12)
0-25% bcl-2-posve tumourcells
(n = 15) P= 0.02
2 1
Years
Fuge 4 Survival of patients with NSCLC in which 50-100%
of tumour ceDs were bcl-2 positive with those whose
tumours contained 0-25% bcl-2-positive tumour cells.
Bcl-2 andp53 expression in bronchial carcinomas
Immunohistochemial expression of the p53 protein in these
tumours had been determined previously (Walker et al.,
1994). No correlation was obtained between bcl-2 expression
and p53 expression.
Dbcw_o
Although expresson of the bcl-2 proten has so far been
investigated in many haematological malignancies and in a
number of solid tumours, few studies have eamined the
distribution of this protein in premalignant lesions.
The bcl-2 protein has been detected by immunohis
tochemical procedures in a limited number of non-lymphoid
tisus under different physiological conditions: in long-lived,
post-mitotic cells (neurones), complex organised epithelia
(skin and gastric intestinal mucosa) and in glandular
epithelium under hormonal control and growth factor cont-
rol (Hockenbery et al., 1991; McDonnel et al., 1992). In
these tisus in which apoptosis accounts for cell turnover,
bcl-2 is topographially restricted to the long-lived progenitor
cells that renew lineages and selected post-mitotic cells that
require an extended lifespan (Hockenbery et al., 1991). In
preous studies bronchial epithelial mucosa has been
reported either not to express bcl-2 (Hockenbery et al., 1991)
or to show positivity in basal cells, with the more
differentiated cells being negative (Lu et al., 1993; Pezzella et
al., 1993). We have found that ls with their nucei in the
basal layer of histologically normal bronchial epithelium exp-
ress bcl-2, resulting in a predominantly basal saining pattern.
However, although the majority of differentiated cells were
negative, in some cases occasional well-diferentiated colum-
nar brush border cells also expressed bl-2. lbe intacellular
distribution of the stain in these occasional differentiated
bronchial epithelial cells and the complance with the
predkied pattern of bcl-2 expression in all other cell types in
these sections and control lymphoid tissue suggests that these
cls do ideed express bcl-2. Furthermore, the monoclonal
antibody clone 124 used in this study is reported to have
satisfatory specificity and has been used in a number of
other studies of both fresh and archival material (Pezzella et
al., 1990, Lauwers et al., 1994; Leek et al., 1994; Pilotti et al.,
1994; Silvestrini et al., 1994; Ramini and Lu, 1994). These
bcl-2-positive differentiated cells were seen in the his-
tologically normal epithelium from cancer and non-cancer
patients and are therefore unlikely to reflect an early event in
the transformation to malignancy. Glandular epithelia such
as breast and thyroid (Hockenbery et al., 1991; Pilotti et a!.,
1994), and in this study bronchial mucosal glands, express
bc!-2, thus bcl-2 positivity m these differentiated bronchial
epithehal cells may be related to secretory function.
lThe bd-2 protein is an integral membrane protein and is
usually a d with a cytoplamic location, being present
in mitochondrial membranes, nuclear outer membranes and
endoplasmic rtulum (Korsmeyer, 1992; Akao et al., 1994;
Lithgow et al., 1994). In this study, occasional cells with
bdl-2-postive nucli were noted in bronchial dysplasias and
carcinomas. In support of this, in some epithelial cell lines
the bcl-2 protein has been shown to have occurred transiently
in mitotic nuclei (Wilingham and Bhalla 1994; Lu et al.,
1994), tng that the anti-apoptotic function of bcl-2
extends into mitosis.
Expression of the bcl-2 protein was altered in all bronchial
epithelial dysplasias examined, suggesting that deregulation
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disorganisation that accompanies dysplasia. It is possible that
the loss of the prominently stained basal layer seen in his-
tologically normal epithelium and the appearance of bcl-2-
positive cells in the upper layers of the epithelium in dysplas-
tic lesions results from the change from a pseudostratifled
columnar to a stratified epithelium in which growth control
has become aberrant. It is likely that initial changes in bcl-2
expression seen in all dysplasias is secondary to other genetic
events which deregulate growth. As bcl-2 is associated in
normal cells with protection from apoptosis (Korsmeyer,
1992; Kerr et al., 1994), bcl-2-positive cells in the upper
layers of the epithelium may evade stringently controlled
normal differentiation and apoptosis and have a growth
advantage compared with bcl-2-negative cells. While staining
patterns A, B and C were found in all histological grades of
dysplasia, pattern D was only observed in some of the severe
dysplasias. The change or changes resulting in this pattern of
bcl-2 expression may therefore be a relatively late, but not
obligatory event in the progression to invasive neoplasia.
This expression pattern may result from a specific genetic
lesion in either the bcl-2 gene or in a gene which controls
bcl-2 expression, occurring relatively late in the development
of malignancy. t(14; 18) translocations which cause overexp-
ression of bcl-2 in some lymphomas (Korsmeyer, 1992) have
not been reported in lung cancers, but immunohistochemical
overexpresson of bcl-2 has been reported in folicular lym-
phomas in the absence of this translocation (Pezzella et al.,
1990).
Aberrant expression of the bcl-2 protein has been reported
in other premalignant lesions. In gastric epithelial dysplasias,
alterations in the spatial distribution of bcl-2-positive cells
were observed, with bcl-2-positive cells being present in
extended regions of the epithelium (Lauwers et al., 1994). In
premalignant keratinocytic tumours, bcl-2 was found to be
expressed in 73% of tumours due to Bowen's disease and in
25% of cases of actinic keratosis, in contrast to surrounding
bcl-2-negative keratinocytes (Nakagawa et al., 1994).
In the initial design of this study, a limited number of
bronchial tumours were examined to determine whether we
obtained a similar distribution of bcl-2-positive cells in
tumour sections to that reported in the literature for other
solid tumours. The bcl-2 protein was found to be distributed
similarly but present in a higher percentage of the bronchial
carcinomas examined in this study than reported by Pezzella
et al. (1993); however, our tumour numbers were much
lower. Because clnical information was available for these
cases, analysis of the chnicopathological data was carried
out, although the conclusions drawn are limited by the small
number ofcases examined. Bcl-2 was expressed in tumours of
all grades of histological differentiation. The only positive
correlation obtained was for survival, and this only when
survival data for patients with tumours with 0-25% bcl-2-
positive tumour cells were compared with those for patients
with tumours with >50% bcl-2-positive cells. Few studies on
the prognostic sign of bcl-2 in NSCLC are as yet
published. In the study by Pezzella et al. (1993) a survival
advantage for patients with bcl-2-positive tumours was
found, particularly for patients with squamous cell car-
cinomas and in those who were over 60 years of age. In this
study the bcl-2-positive group was compared with the bcl-2-
negative group (Pezzella et al., 1993). It is notable that
Silvestrini et al. (1994), in their study of the prognostic
signii of bcl-2 expression in breast carcinomas, com-
pared survival data for patients with more than 30% bcl-2-
positive cells with those for patients with lower positivity.
The relationship of bcl-2 expression to prognosis and sur-
vival in non-haematological malignancies is currently poorly
defined. In some studies, bcl-2 expression is associated with a
survival advantage (NSCLC, Pezzella et al., 1993; breast,
Silvestrini et al., 1994) and markers of good prognosis
(breast, Leek et al., 1994), while in others it has no effect
(neuroblastoma, Ramini and Lu, 1994) or is related to poor
prognosis (neuroblastoma, Castle et al., 1993). While it can
be argued that retention of bcl-2 expression in tumours may
protect against apoptosis and lead to abnormal accumulation
of malignant cells (Korsmeyer, 1992; Kerr et at., 1994),
overexpression of bcl-2 has been found to lead to growth
inhibition in some cultured cancer cell lines (Pietenpol et al.,
1994). These observations suggest that further investigation
of bcl-2 expression in a larger series of NSCLCs than
hitherto reported would be justified to assess the clinical
utility of this marker.
Both the bcl-2 and p53 genes are involved in the genetic
control of apoptosis (Haldar et al., 1994; Miyashita et al.,
1994a). Recent research has shown that there is a negative
response element in the bcl-2 gene through which p53 may
directly or indirectly transcriptionally down-regulate the bcl-2
gene (Miyashita et al., 1994b). In breast and some thyroid
carcinomas and non-Hodgkin's lymphoma, an inverse cor-
relation between the immunohistochemical expression of p53
and bcl-2 has been demonstrated (Pezzella et al., 1992; Silves-
trim et al., 1994; Leek et al., 1994; Pilotti et al., 1994). In
contrast, no correlation between p53 and bcl-2 expression
was observed in this study in either bronchial dysplasias or
carcinomas.
In this study, we have shown that abnormal expression of
the bcl-2 protein is present in bronchial dysplasias of all
histological grades, suggesting that changes in the expression
of this molecule arise early in the transformation of normal
to dysplastic epithelium. Further alterations in its expression
may occur late in the progression to malignancy. Before
expression of this protein could be used as a biomarker for
malignancy, further investigation of the expression of this
gene and its biological and prognostic significance in lung
cancer is essential.
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